Table 1 Baseline patient and disease characteristics in ATOS as compared to the ATLG treatment arm of our RCT.
Baseline characteristics | ATOS N = 165 | ATLG (RCT) N = 103 |
|---|---|---|
Patient age (median, [min; max]) | 54 [18; 77] | 40 [18; 60] |
< 40 years | 26 (15.8%) | 47 (45.6%) |
≥ 40 years | 139 (84.2%) | 56 (54.4%) |
Donor age (median, [min; max]) | 32 [19; 67] | 35 [20; 58] |
< 40 years | 112 (67.9%) | 62 (66.0%) |
≥ 40 years | 53 (32.1%) | 32 (34.0%) |
Patient/Donor sex | ||
Patient male/Donor female | 20 (12.2%) | 14 (13.9%) |
Other | 144 (87.8%) | 87 (86.1%) |
Patient CMV status | ||
Positive | 83 (50.3%) | 66 (64.1%) |
Negative | 82 (49.7%) | 37 (35.9%) |
Donor CMV status | ||
Positive | 66 (40.0%) | 48 (46.6%) |
Negative | 99 (60.0%) | 55 (53.4%) |
Type of primary disease | ||
AML | 89 (53.9%) | 55 (53.4%) |
ALL | 24 (14.5%) | 37 (35.9%) |
MDS | 17 (10.3%) | 5 (4.9%) |
CML | 3 (1.8%) | 6 (5.8%) |
OMF | 6 (3.6%) | 0 (0.0%) |
Other | 26 (15.8%) | 0 (0.0%) |
Disease status | ||
Early | 75 (45.5%) | 64 (62.1%) |
Intermediate | 29 (17.6%) | 15 (14.6%) |
Advanced | 61 (37.0%) | 24 (23.3%) |
Conditioning intensity | ||
Myeloablative (MAC) | 81 (50.9%) | 103 (100.0%) |
Reduced intensity conditioning | 78 (49.1%) | 0 (0.0%) |
(RIC) | ||
Other/missing | 6 | |
Time from primary diagnosis of current disease to transplantation | ||
< 1 year | 121 (73.3%) | 84 (81.6%) |
≥ 1 year | 44 26.7%) | 19 (18.4%) |
Stem cell source | ||
Bone marrow | 6 (3.6%) | 21 (20.4%) |
Peripheral blood | 159 (96.4%) | 82 (79.6%) |
HLA mismatch (10/10, 4-digit) | 37 (22.4%) | 31 (33.7%) |
ATLG dose (median, [min; max]) | ||
absolute given total dose per kg | 46 [15; 91] | 60 [19; 65] |
< 45 mg/kg | 81 (49.1%) | 6 (5.8%) |
≥ 45 mg/kg | 84 (50.9%) | 97 (94.2%) |
